{"organizations": [], "uuid": "81893770cee7062c5d7cf1ad389250309f6382fd", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-myriad-genetics-announces-expanded/brief-myriad-genetics-announces-expanded-research-collaboration-with-astrazeneca-idUSFWN1OY0BU", "country": "US", "domain_rank": 408, "title": "BRIEF-Myriad Genetics Announces Expanded Research Collaboration With AstraZeneca", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-03T14:12:00.000+02:00", "replies_count": 0, "uuid": "81893770cee7062c5d7cf1ad389250309f6382fd"}, "author": "", "url": "https://www.reuters.com/article/brief-myriad-genetics-announces-expanded/brief-myriad-genetics-announces-expanded-research-collaboration-with-astrazeneca-idUSFWN1OY0BU", "ord_in_thread": 0, "title": "BRIEF-Myriad Genetics Announces Expanded Research Collaboration With AstraZeneca", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "astrazeneca", "sentiment": "negative"}, {"name": "reuters staff  jan", "sentiment": "none"}, {"name": "myriad genetics inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 13 PM / in 12 minutes BRIEF-Myriad Genetics Announces Expanded Research Collaboration With AstraZeneca Reuters Staff \nJan 3 (Reuters) - Myriad Genetics Inc: \n* MYRIAD GENETICS ANNOUNCES EXPANDED RESEARCH COLLABORATION WITH ASTRAZENECA \n* MYRIAD GENETICS INC - FINANCIAL TERMS WERE NOT DISCLOSED. \n* MYRIAD GENETICS INC - UNDER AGREEMENT, MYRIAD WILL USE ITS MYCHOICE HRD PLUS TEST TO EVALUATE PATIENTS ENROLLED IN AN ONGOING PHASE III TRIAL Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-01-03T14:12:00.000+02:00", "crawled": "2018-01-03T14:29:04.011+02:00", "highlightTitle": ""}